Osmind

06/04/2026

Less than 1% of the people who'd qualify for TMS ever get it.
Scott West, MD, brought TMS to Tennessee in 2010. Fifteen years later, he says the problem is awareness.

A 40-year-old patient of his grew up two miles from his clinic, in a family touched by depression and su***de, and had never heard of TMS until the week she walked in.

William Sauvé, MD sat down with him for the latest episode of Psychiatry Tomorrow:

•He stopped calling TMS a depression treatment – and started calling it a tool that treats the brain

•"Take a pill, come back in six weeks" isn't good enough for a condition this serious

•Going off-label responsibly: fibromyalgia, a nine-year-old with Tourette's, and how to read the research

•Where TMS is headed: QEEG-guided protocols, new circuits, EEG captured under a live coil

"I think depression is an urgent illness to deal with." – Scott West, MD

Search "Psychiatry Tomorrow" wherever you listen, or find the link below. 👇

Dr. Scott West brought TMS to Tennessee in 2010. Why do so few patients get TMS for treatment-resistant depression, and how can clinicians close the gap?

05/27/2026

Osmind is a proud sponsor of the Clinical TMS Society's 14th Annual Meeting and Foundation for the Advancement of Clinical TMS (FACTMS), both working to expand TMS access and raise the clinical bar for the field.

William Sauvé, MD is presenting a poster on 'Defining Interventional Psychiatry: A Framework to Elevate and Integrate TMS Practice.'

Primary care already writes ~70% of psychiatric prescriptions. If psychiatry reduces to evaluation and prescription, what makes it distinct?

The poster makes the case that the answer is procedural intervention, led by TMS. And a clear definition of interventional psychiatry gives the field the identity, credentialing logic, and advocacy posture it's been missing.

The poster is co-authored with Thomas Insel MD, Stephen M. Stahl, MD, PhD, DSc(Hon), DMedSci (Hon, Cambridge), Husseini Manji, MD, FRCPC, Roger McIntyre, Brittany Albright MD, MPH, DABOM, Martha B. Koo, M.D., LFAPA, FASAM, FCTMSS, Robert Berman, and Jimmy Qian.

Attending? Find us at the booth 305, or the poster session.

05/26/2026

We'll be at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, May 26–29, with two new posters on real-world outcomes in interventional psychiatry:

1️⃣ IV racemic ketamine vs. intranasal esketamine in MDD (n=3,560 matched patients) with Yale School of Medicine

2️⃣ Psychedelic preparedness and experiential predictors of outcomes from Oregon's legal psilocybin program, with Bendable Therapy and University of California, San Francisco. This builds on the first real-world outcomes data from Oregon's Measure 109 program that we unveiled at Psych Congress 2025.

Both aim to answer how these treatments perform in routine clinical care, beyond the trial setting.

If you're headed to Miami May 26–29, come say hi!

05/20/2026

Couldn't make it to APA 2026? Or you were there and want to compare notes?

Join us this Tomorrow, Thursday, May 21 for a live, informal lunch chat: APA 2026 Recap—Clinical Takeaways & Practice Tools You Can Use Now.

Sit down with Brittany Albright MD, MPH, DABOM, William Sauvé, MD, and fellow Psychiatry Collective members for an open conversation about what actually mattered at APA this year—no slides, no lectures, just real talk between clinicians.

On the table:
→ Key clinical findings and themes from APA 2026
→ What's new in interventional psychiatry (Spravato, TMS, psychedelics)
→ Practice management tools and workflows you can implement today
→ Whatever else you want to bring up

It's an open mic format—bring your questions live, or drop them in the comments and we'll cover them during the chat.

🗓 Thursday, May 21 | 11 am PT / 2 pm ET 🔗 RSVP:

The Psychiatry Collective is Osmind's community for clinicians advancing interventional psychiatry. Free to join.

hashtag hashtag hashtag

05/19/2026

Osmind is proud to be collaborating with Compass Pathways to help independent psychiatry practices prepare for the potential future delivery of psychedelic medicine.

Independent practices are where the vast majority of patients receive their care. But they've historically been left behind when it comes to adopting innovative treatments, because the operational burden is simply too high.

Together with Compass, we're working to change that.

Run an independent psychiatry practice and want to stay ahead of what's coming?

Swipe through to stay in the loop on readiness resources as they're released →

05/18/2026

When evaluating a PTSD patient for ketamine infusion therapy, the trauma profile may tell you more than the depression score. That's one takeaway from a poster we presented over the weekend: "Baseline PTSD and Depression Severity Moderate Real-World Response to Ketamine for PTSD."

In a real-world study of 1,340 patients, William Sauvé, MD, L. Alison McInnes MD, MS. Jimmy Qian, and Emily Shih found:

→ Patients with the highest baseline PTSD burden improved the fastest
→ Baseline PTSD severity introduced more variation in treatment response than depression severity did
→ Improvement occurred across all levels of depression severity, but PTSD trajectories were more sensitive to where patients started I

If you’re at the American Psychiatric Association (APA) annual meeting, feel free to reach out!

05/11/2026

We'll be at the APA Annual Meeting in San Francisco later this week. Here's where to find us:

📊 Poster: "Baseline PTSD and Depression Severity Moderate Real-World Response to Ketamine for PTSD" — Sauvé WM, McInnes LA, Qian JJ, Shih E. Using data from 1,340 patients, this study examines how baseline PTSD and depressive symptom severity shape treatment trajectories during ketamine infusion therapy.

🎤 Panel: "From Specialty to Standard: How Do We Scale Interventional Psychiatry” Will Sauvé joins Carlene MacMillan, Mimi Winsberg, Andrew Ge**er, and Owen Muir.

If you're attending and want to connect about our collaboration with the APA, measurement-based care, real-world evidence, or what it takes to scale interventional treatments, we'd love to meet. Reach out or find us on-site.

05/07/2026

As we gear up for the American Psychiatric Association (APA) Annual Meeting in our home base of San Francisco, we’re proud to share that our latest research in collaboration with the APA on the DSM-5 Cross-Cutting Symptom Measure has been published in Frontiers in Psychiatry.

Using real-world data from Using real-world data from 3,101 patients across 169 psychiatric practices in 48 states, we identified six distinct symptom dimensions and evidence of a general psychopathology factor—supporting the DSM-XC as a practical tool for dimensional assessment in outpatient psychiatry.

This is especially relevant as the APA’s DSM Committee aims to leverage data and precision in constructing the next iteration of the field’s diagnostic framework.

This is the kind of work that gets us excited about what a Learning Health System can do: turning routine measurement-based care into evidence that shapes how we screen and treat mental health conditions.

BackgroundDimensional approaches to psychiatric assessment are increasingly used to complement categorical diagnoses. The DSM–TR Level 1 Cross-Cutting Sympto...

05/04/2026

Struggling to keep up with what’s actually working in interventional psychiatry right now?

Join us live within the Psychiatry Collective for an Interventional Psychiatry Office Hours with Martha B. Koo, M.D., LFAPA, FASAM, FCTMSS.

🗓️ May 7 | 11:00 AM PT / 2:00 PM ET

A casual, clinician-led conversation on real-world practice.

05/01/2026

"I knew I wanted to add Spravato to my practice—I just didn't want to deal with the credentialing piece." That's the gap most clinicians hit when they want to expand into interventional treatments.

Wanting to offer something life-changing for patients, but staring down months of credentialing, billing setup, and prior auth workflows.

Osmind handles all of it, so practices can expand care with insurance-backed treatments like TMS and Spravato, and get paid well in the process.

Free credentialing for a limited time.